Safety and Efficacy of Brimonidine in Patients With Glaucoma or Ocular Hypertension

Phase 3CompletedNCT00168363

Allergan207 enrolled

Overview

This Study will evaluate the safety and efficacy of brimonidine in patients with glaucoma or ocular hypertension

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

207

Conditions

Glaucoma Ocular Hypertension

Interventions

brimonidineDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * ocular hypertension or glaucoma in both eyes * currently treated with brimonidine * requires IOP-lowering therapy in both eyes Exclusion Criteria: * uncontrolled systemic disease * known allergy or sensitivity to brimonidine

Outcomes

Primary Outcomes

lowering of intraocular pressure

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.